Neal G. Koller, President and CEO
    Mr. Koller started his career with Wyeth Pharmaceuticals where he made
    notable contributions over his 18 years with the company.  Those
    achievements include:  General Manager for two different start-up divisions
    growing one to $ 50M annualized revenues within 11 months of regulatory
    approvals and the other to a 25% share in the US and launch in Europe within
    18 months of regulatory approvals; VP of a $ 120M Operating Room and
    Critical Care Division where he doubled earnings within 3 years through 3
    acquisitions, 1 divestiture and introduction of a large portfolio of new products.

Following Wyeth, Mr. Koller joined as President WelCare Industries Spa, a European medical
device start-up company where he guided the company past its first $1M in revenues within its
first 2 years.  He continues to serve the company as a member of its board of directors.  Mr. Koller’
s extensive startup responsibilities included:  CEO of Sound Diagnostics, Inc., a spinout company
of Siemens AG, where he negotiated the first $5.6 million to launch the company and Dovetail
Technologies, Inc., where, as CEO and President, he raised the capital necessary to move its
second molecule into Phase I/II clinical trials.  Mr. Koller comes to PluroGen™ after completing a
successful turnaround of the prestigious Bio/Pharmaceutical industry organization, the Parental
Drug Association, where he reversed revenue and profit decline in all four business units and
developed closer ties to US FDA, Europe’s EMEA and a number of national health authorities
around the world.

Glenn D. Warden, MD, MBA, FACS, Chief Medical Officer
    Glenn Warden received his M.D. from the University of Utah in 1968.  His
    distinguished career in burn surgery began with a research fellowship at the
    United States Army Institute of Surgical Research Burn Unit at Brooke Army
    Medical Center (1971-1974).  In 1976, he was appointed to the surgical faculty
    at the University of Utah, rising to full Professorship in 1985.  He served as
    Director of the Intermountain Burn Center and the Trauma Division in the
    Department of Surgery from 1977 to 1985.  In 1985, he became Professor of
    Surgery at the University of Cincinnati, College of Medicine, Director of the Burn
    Division of the Department of Surgery and the Chief of Staff of the Shriners
Hospital for Children – Cincinnati Burns Hospital. He was appointed Vice-Chairman of the
Department of Surgery in 1997.  In 1999, he received a Masters of Business Administration from
Xavier University in Cincinnati, Ohio. Dr. Warden has authored over 600 manuscripts in burn care
and serves as Emeritus Editor-in-Chief for the Journal of Burn Care & Rehabilitation.  He was
President of the American Burn Association (ABA) from 1992-1993 and recipient of the coveted
Harvey Stuart Allen Distinguished Service Award in 1997 and the American Burn Association
Special Achievement Award in 2006.  He chaired the General and Plastic Surgery Devices Council
of the Food and Drug Administration in 1992 and contributes to several medical advisory boards
and 39 professional societies.  Dr. Warden is currently Adjunct Professor of Surgery, University of
Utah, Professor of Surgery Emeritus, University of Cincinnati, Emeritus Chief of Staff of the
Shriners Hospital for Children, Cincinnati Burns Hospital and Staff Surgeon, Intermountain Shrine
Hospital for Children, Salt Lake City, Utah.

He retired as chief of staff in 2004  He presently serves as CEO of Warden BioScience Associates
in Salt Lake City, Utah.

©2009 PluroGen Therapeutics, Inc.